anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In data collection, pregnant women will sign an informed consent form before the application. At least 4 hours after the antiemetic administration, the Personal Information Form, VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled out. Routine treatment and nursing care will be applied to the control group, and no intervention will be performed. 1. After the forms are applied, the forms will continue to be filled for 3 days: VAS Scale in the morning, VAS Scale in the evening, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale. The forms of discharged patients will be filled in via phone.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to the field of pharmaceutical industry and medicine and is intended for treatment of wounds and burns. Analgetic and wound healing agent is described, having the following composition, wt %: polyvinylpyrrolidone - 2-10, agar - 1-3, polyethylene oxide - 1-3, lidocaine hydrochloride - 0.01-5.0, water - balance. Agent is produced by linkage of medical-purpose polymers under action of ionising radiation. ^ EFFECT: agent has elasticity, tensile strength, sorbtion effect relative to wound exudate, transparency, which makes it possible to follow course of wound process, painless removal from wound surface, creates optimal microclimate in wound (humidity, temperature), provides for wound healing and analgetic effects. ^ 3 ex
1,256,418. Cosmetic barrier compositions. GILLETTE CO. 19 May, 1969 [22 May, 1968], No. 25410/69. Heading A5B. [Also in Division C3] A water-or detergent-barrier composition comprises a dermatologically acceptable vehicle and a solution in an organic solvent of an ester of a C 6-22  fatty acid and starch, amylose or amylopectin, at least 50% of the hydroxyl groups of which are esterified. The barrier compositions may be in the form of a cream, ointment, aerosol composition stick, or lotion and may contain other conventional ingredients which render them useful as a moisturizing lotion, deodorant, sun tan cream or makeup base.
FIELD: medicine, pharmaceutical industry. SUBSTANCE: invention relates to agents stimulating reparative process in tissues. Invention proposes the composition containing stimulator of reparative processes etaden, special additions ethonium and trimecainum and a base. An aqueous-polyethylene oxide solution, glycerol-polyethylene oxide solution and emulsion base of type "oil-in-water" are used as the base. Invention provides effective treatment of wounds and burns at all stages of wound process. EFFECT: enhanced effectiveness of composition. 4 cl, 3 tbl
The present invention relates to a composition of cold spring volcanic mud and pure bioactive factors and a processing method thereof, wherein the processing method is used for producing the composition of cold spring volcanic mud and pure bioactive factors. When people adopt volcanic mud as a health product, mineral matters and trace elements are immersed in skin, and simultaneously, skin discomfort and skin diseases can be caused frequently. The composition of cold spring volcanic mud and pure bioactive factors is used as a product for beauty treatment and skin maintenance. The present invention also provides the processing method for the composition of cold spring volcanic mud and pure bioactive factors. The composition of cold spring volcanic mud and pure bioactive factors comprises the cold spring volcanic mud and the freeze-drying powder of the pure bioactive factors according to the weight ratio is 10000 to 5. The composition is used for preparing cosmetics, restoring wounds, enhancing the restorability of epidermal cells and replenishing trace elements.
The leader uses a digital cognitive aid designed as a smartphone app during advanced combat casualty care. Intervention: Device: SIMMAXMARCHERYAN2 Digital cognitive aid during the management of simulated war wounded.
The present invention pertains to the prevention or lessening of disease in cats caused by Feline Immunodeficiency Virus (FIV). Prevention or lessening of disease is understood to mean the amelioration of any symptoms, including immune system disruptions, that results from FIV infection. The invention provides recombinant proteins produced in a baculovirus expression system having at least one internal gene comprising a DNA sequence that encodes either the entire FIV env region (ENV-ABC), or a DNA sequence consisting of viral nucleotides 6252-8469 of FIV env (ENV-AB), a DNA sequence consisting of viral nucleotides 6252-6722 and 8264-9140 of FIV env (ENV-AC), or immunogenic fragments of any of the foregoing either singly or in combination. By immunogenic fragment is meant any portion of the coding sequence of FIV env polypeptides that induces a beneficial immune response in cats. In another embodiment, the invention encompasses vaccines that comprise one or more of the baculovirus-expressed recombinant FIV proteins described above, with a pharmaceutically acceptable carrier or diluent and a pharmaceutically acceptable adjuvant. In yet another aspect, the invention provides methods for preventing or lessening disease caused by FIV, which is carried out by administering to a feline in need of such treatment the vaccines described above.
The optimal treatment for paraesophageal hiatus hernia (PEH) is controversial. While crural buttressing with mesh shows promises in reducing recurrences, the decision to use mesh during minimally invasive PEH repair is largely subjective. Due to these uncertainties, we conducted a survey to examine current clinical practices among surgeons and to assess which are the most important determinants in the decision-making process for mesh placement. Thirty-five multiple-choice Google Form-based survey on work-up, surgical techniques, and issues are considered in the decision-making process for mesh augmentation during minimally invasive PEH repair. Responses were graded on a 5-point Likert scale and analyzed using descriptive statistics. Consensus was defined as > 70% of participants agreed (agree or strongly agree) on a specific statement. Overall, 292 surgeons (86% from Europe) participated in the survey. The median age of participants was 42 years (range 29-69). The median number of PEH procedures was 25/year/center (range 5-400), with 67% of participants coming from high-volume centers (> 20 procedures/year). Consensus on use of mesh was reached for intraoperative findings of large (> 50% of intrathoracic stomach) PEH (74.3%), crural gap with > 4 cm distance between right and left crus (77.1%), and/or crural atrophy with < 0.5 cm thickness of one or both pillars (73%), and for redo surgery (71.9%). Further, consensus was reached in defining recurrence as a combination of refractory symptoms and anatomical/radiological evidence of > 2 cm hernia. This survey shows that large PEH, wide crural transverse diameter, fragile crura, and redo surgery are the most influential issues driving the decision for mesh-reinforced cruroplasty.
Significant caregivers in AN patients aged 14 to 15 years: parents; in AN patients aged 16 years and over: parents or other significant carer. No intervention.
PURPOSE: A composition containing abalone extract is provided to ensure antioxidation activity without safety and side effects and to be used in a cosmetic product and health foods. CONSTITUTION: A cosmetic composition for skin aging contains abalone extract as an active ingredient. Abalone includes Haliotis discus hannai, H. gigantean, H. discus, H. sieboldii, or H. diversicolor superfextra. The abalone extract is prepared by extracting abalone intestine or muscle using hexane, ethyl acetate, 25-100% ethanol, and distilled water in order. The abalone extract is prepared by extracting abalone intestine or muscle using methanol and fractioning the methanol extract with hexane, ethyl acetate, and butanol in order. The abalone extract is also prepared using Proteomix. [Reference numerals] (A1,A2) Intestine; (B1,B2) Muscle
Growing evidence confirms associations between glycogen metabolic re-wiring and the development of liver cancer. Previous studies showed that glycogen structure changes abnormally in liver diseases such as cystic fibrosis, diabetes, etc. However, few studies focus on glycogen molecular structural characteristics during liver cancer development, which is worthy of further exploration. In this study, a rat model with carcinogenic liver injury induced by diethylnitrosamine (DEN) was successfully constructed, and hepatic glycogen structure was characterized. Compared with glycogen structure in the healthy rat liver, glycogen chain length distribution (CLD) shifts towards a short region. In contrast, glycogen particles were mainly present in small-sized β particles in DEN-damaged carcinogenic rat liver. Comparative transcriptomic analysis revealed significant expression changes of genes and pathways involved in carcinogenic liver injury. A combination of transcriptomic analysis, RT-qPCR, and western blot showed that the two genes, Gsy1 encoding glycogen synthase and Gbe1 encoding glycogen branching enzyme, were significantly altered and might be responsible for the structural abnormality of hepatic glycogen in carcinogenic liver injury. Taken together, this study confirmed that carcinogenic liver injury led to structural abnormality of hepatic glycogen, which provided clues to the future development of novel drug targets for potential therapeutics of carcinogenic liver injury.
Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
Hepatitis B virus (HBV) is a leading cause of chronic liver disease globally, with devastating complications such as cirrhosis, hepatocellular carcinoma and death. Vertical transmission (VT) of HBV is a worldwide public health concern because infected children are at high risk of developing chronic liver disease. It is a particular problem in the Democratic Republic of the Congo (DRC); preliminary data suggest that approximately 3% of children have HBV infection due to VT. However, VT is preventable. Pregnant women with risk factors can be identified and treatments given which can virtually eliminate transmission. Unfortunately, despite the high burden of HBV, neither HBV testing of pregnant women nor interventions to prevent HBV VT are routinely performed in the DRC and elsewhere in sub-Saharan Africa. This pilot feasibility study will address this healthcare gap by identifying women with HBV early in their pregnancies and intervening to prevent VT by (1) treating mothers with high-risk HBV (defined as HBeAg positivity and/or HBV viremia \>10\^6) with tenofovir and (2) providing HBV vaccine to HBV-exposed infants within 24 hours of birth. This pilot study will piggyback onto an existing study that is evaluating the DRC's HIV Prevention of Maternal-to-Child Transmission Option B+ (PMTCT+) strategy. Combining programs to prevent VT of HBV and HIV enables using the same personnel and infrastructure to implement both interventions. Furthermore, tenofovir, used to treat HBV infections, is already used in the DRC to treat HIV. Researchers hypothesize that utilizing the existing PMTCT+ infrastructure in the DRC will provide a cost-effective platform to prevent HBV VT. If effective, this model of treatment will inform future public health efforts and wider policy recommendations that can be applied in the DRC and throughout the Sub-Saharan African region to reduce the burden of HBV.
Poxviruses remain a significant public health concern due to their potential use as bioterrorist agents and the spread of animal borne poxviruses, such as monkeypox virus, to humans. Thus, the identification of small molecule inhibitors of poxvirus replication is warranted. Vaccinia virus is the prototypic member of the  Orthopoxvirus  genus, which also includes variola and monkeypox virus. In this study, we demonstrate that the carboxylic ionophore nigericin is a potent inhibitor of vaccinia virus replication in several human cell lines, in HeLa cells, we found that the 50% inhibitory concentration of nigericin against vaccinia virus was 7.9 nM, with a selectivity index of 1038. We present data demonstrating that nigericin targets vaccinia virus replication at a post-entry stage. While nigericin moderately inhibits both early vaccinia gene transcription and translation, viral DNA replication and intermediate and late gene expression are severely compromised in the presence of nigericin. Our results demonstrate that nigericin has the potential to be further developed into an effective antiviral to treat poxvirus infections.
The experimental group will receive a positive end-expiratory pressure (PEEP, +/- noninvasive positive pressure ventilation) and nebulised surfactant via a customised vibrating membrane nebuliser. Nebulisation will commence with the first application of a PEEP and will continue for a maximum of 30 minutes.
BACKGROUND: Filiano and Kinney proposed a triple-risk model for the sudden infant death syndrome (SIDS) that involves the intersection of three risks: (1) a vulnerable infant, (2) a critical developmental period in homeostatic control, and (3) an exogenous stressor(s). The primary evidence for the role of a critical developmental period in SIDS etiology is the peak of cases around the third month of life. Independently, several studies pointed to correlation between gestational age and age at death in SIDS, but used that to assess the SIDS risk for preterm infants, ignoring further ramifications.
METHODS: We did a detailed analysis of CDC data spanning over two decades (1983-2011). We focused not only on the correlation between two age variables (gestational and age at death), but also on the possibility of misdiagnosis. Also, we attempted to account for potential biases in the data induced by the ICD-9/ICD-190 transition or the "Back to Sleep" campaign.
RESULTS: The peak of deaths in the third month of life, that was the main argument for the role of the critical development period, wasn't unique to SIDS. However, we confirmed an almost linear and negative correlation between gestational age and the week of death due to SIDS. This pattern (slope of correlation < 0 and significance of correlation p < 0.05) is characteristic of SIDS among all diseases analyzed in the study.
CONCLUSIONS: We interpret the results as the evidence of the role of the critical development period in SIDS etiology. Possibly more attention in the future research should be put to theories that are based on homeostatic control.
Cyclodextrin (or a derivative) which incorporates a drug which can be released on contact with body fluid, is fixed to a textile material (e.g. a T shirt) which can be used for transdermal delivery of drugs. Textile material (e.g. a fiber, filament or yarn), to which cyclodextrin (or a cyclodextrin derivative) is attached, is new.  The cyclodextrin (derivative) incorporates a pharmaceutical active agent. The active agent is released from the cyclodextrin (derivative) on contact with a body fluid.
The invention discloses marine polysaccharide-based dry mouth symptom relieving mouthwash and a preparation method thereof. A composition, namely the marine polysaccharide-based dry mouth symptom relieving mouthwash, comprises the active ingredients, such as alginate and chitosan derivatives, and also comprises an inorganic salt, a preservative and water. The preparation method comprises the following steps: dissolving the alginate and the chitosan derivatives into water, stirring for dissolving for a certain time at a certain temperature, adding the inorganic salt and the preservative into the solution, filtering to remove impurities, and metering the volume of a filtrate to obtain the product. The marine polysaccharide-based dry mouth symptom relieving mouthwash has the characteristic of lightening chronic and temporary dry mouth caused by diseases, medicine use, radiotherapy and chemotherapy, senescence and the like, and can lubricate and wet soft and hard tissues in an oral cavity to relieve the dry mouth symptom of a patient with the dry mouth symptom. The product has good water holding capacity, so that the wet keeping time of the oral cavity can be prolonged, and the pain caused by dry mouth of the patient is lightened; meanwhile, the oral cavity can be cleaned and halitosis can be prevented. The marine polysaccharide-based dry mouth symptom relieving mouthwash and the preparation method thereof have the characteristics of remarkable treatment effect, simple preparation method, low cost and the like; the dry mouth symptom relieving mouthwash can be used as a medicine for treating the dry mouth symptom.
Participants with non-small cell lung cancer (NSCLC) will be randomized to receive low dose or high dose of RDE of TAK-186 infusion on Day 1 of every week during Dose Expansion Phase of the study. Participants may receive additional treatment with TAK-186. Based on the results for this cohort additional cohorts for HNSCC and CRC, may be enrolled.
INTRODUCTION: Accurate assessment of the depth of tumor invasion in gastric cancer (GC) is vital for the selection of suitable patients for neoadjuvant chemotherapy (NAC). Current problem is that preoperative differentiation between T1-2 and T3-4 stage cases in GC is always highly challenging for radiologists.
METHODS: A total of 129 GC patients were divided into training (91 cases) and validation (38 cases) cohorts. Pathology from surgical specimens categorized patients into T1-2 and T3-4 stages. IVIM-DWI and MRI morphological characteristics were evaluated, and a multimodal nomogram was developed. The MRI morphological model, IVIM-DWI model, and combined model were constructed using logistic regression. Their effectiveness was assessed using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC).
RESULTS: The combined nomogram, integrating preoperative IVIM-DWI parameters (D value) and MRI morphological characteristics (maximum tumor thickness, extra-serosal invasion), achieved the highest area under the curve (AUC) values of 0.901 and 0.883 in the training and validation cohorts, respectively. No significant difference was observed between the AUCs of the IVIM-DWI and MRI morphological models in either cohort (training: 0.796 vs. 0.835, p = 0.593; validation: 0.794 vs. 0.766, p = 0.79).
CONCLUSION: The multimodal nomogram, combining IVIM-DWI parameters and MRI morphological characteristics, emerges as a promising tool for assessing tumor invasion depth in GC, potentially guiding the selection of suitable candidates for neoadjuvant chemotherapy (NAC) treatment.
Nisoldipine pharmacokinetics are independent of the dose across the clinical dosage range of 17 mg to 51 mg, with plasma concentrations proportional to dose. Nisoldipine accumulation, during multiple dosing, is predictable from a single dose. Nisoldipine is relatively well absorbed into the systemic circulation with 87% of the radiolabeled drug recovered in urine and feces. The absolute bioavailability of nisoldipine is about 5%. Nisoldipine’s low bioavailability is due, in part, to pre-systemic metabolism in the gut wall, and this metabolism decreases from the proximal to the distal parts of the intestine. A pronounced food-effect is observed when nisoldipine extended-release tablets are administered with a high-fat meal resulting in an increased peak concentration (Cmax) of up to 245%. Total exposure (AUC) is decreased by 25%. As a result, nisoldipine extended-release tablets should be taken on an empty stomach (1 hour before or 2 hours after a meal).

Maximal plasma concentrations of nisoldipine are reached at 9.2 ± 5.1 hours. The terminal elimination half-life (reflecting post absorption clearance of nisoldipine) ranges from 13.7 ± 4.3 hours. After oral administration, the concentration of (+)-nisoldipine, the active enantiomer, is about 6 times higher than the inactive (-)-nisoldipine enantiomer. The plasma protein binding of nisoldipine is very high, with less than 1% unbound over the plasma concentration range of 100 ng/mL to 10 mcg/mL.

Nisoldipine is highly metabolized; 5 major urinary metabolites have been identified. Although 60% to 80% of an oral dose undergoes urinary excretion, only traces of unchanged nisoldipine are found in urine. The major biotransformation pathway appears to be the hydroxylation of the isobutyl ester. A hydroxylated derivative of the side chain, present in plasma at concentrations approximately equal to the parent compound, appears to be the only active metabolite, and has about 10% of the activity of the parent compound. Cytochrome P450 enzymes are believed to play a major role in the metabolism of nisoldipine. The particular isoenzyme system responsible for its metabolism has not been identified, but other dihydropyridines are metabolized by cytochrome P450 IIIA4. Nisoldipine should not be administered with grapefruit juice, as this has been shown, in a study of 12 subjects, to interfere with nisoldipine metabolism, resulting in a mean increase in Cmax of about 3-fold (ranging up to about 7-fold) and AUC of almost 2-fold (ranging up to about 5-fold). A similar phenomenon has been seen with several other dihydropyridine calcium channel blockers.
Obesity is recognized as a major risk factor for chronic kidney disease (CKD), which is accompanied by increased renal lipid build-up, fibrosis, inflammation, apoptosis and pyroptosis. Bicyclol (BIC), a Chinese marketed hepatoprotective drug, has shown excellent anti-inflammatory, anti-fibrosis, anti-apoptotic, and lipid regulation effects in different animal models. In this study, we explored the role and mechanism of BIC in high-fat diet (HFD)-induced obesity-related nephropathy. Mice were fed with HFD for 24 weeks to develop obesity-related nephropathy, while mice in the BIC administration group were treated with BIC (50 mg/kg or 100 mg/kg, once every two days) at the last 12 weeks. We found that BIC treatment relieved the impairment of kidney structure and renal dysfunction caused by HFD. In addition, we found that BIC mitigated HFD-induced renal fibrosis, inflammation, apoptosis and pyroptosis by inhibiting JNK and NF-κB pathways. SV40-MES-13 cells treated with palmitate (PA) were used as the in vitro model. Our data show that BIC pre-administration relieved cellular damage caused by PA through suppressing JNK and NF-κB signaling pathways. In conclusion, we demonstrated that BIC attenuated obesity-induced renal injury by inhibiting chronic inflammation, fibrosis, apoptosis and pyroptosis via targeting JNK and NF-κB pathways. Our data suggested that BIC could be potentially used to prevent obesity-associated nephropathy, which warrants future investigation.